<DOC>
	<DOCNO>NCT01720238</DOCNO>
	<brief_summary>Though newly report HBV infection HBsAg prevalence China greatly decrease , patient chronically infected HBV , especially liver cirrhosis cause great burden public health care . In view economic development level , drug availability lack independent health economics evidence , investigator still unable give specific guideline HBV relate compensate liver cirrhosis China . Therefore , investigator aim investigate clinical effect cost-effectiveness two early anti-viral therapy strategy HBV relate compensate liver cirrhosis prospective , open-label , multicenter nonrandomized study .</brief_summary>
	<brief_title>Clinical Effects Cost-effectiveness Analysis Early Anti-viral Therapy HBV-related Compensated Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>write informed consent age 1870 year clinical diagnosis compensate liver cirrhosis 1. liver biopsy show cirrhosis 2. endoscopy : esophageal varix , exclusion noncirrhotic portal hypertension 3. biopsy endoscopy ，should meet two four : Imaging ( US , CT MRI , et al ) show Surface nodularity： Echogenecity （spleen pachydiameter &gt; 4.0cm &gt; 5 costal region） PLT &lt; 100×10 &lt; 9 &gt; /L，no interpretation ALB &lt; 35.0 g/L , INR &gt; 1.3 , CHE &lt; 5.0KU/L Liver stiffness measurement value &gt; 12.4 kpa HBeAg ( + ) HBVDNA &gt; 10 &lt; 3 &gt; IU/mL HBeAg ( ) wtih HBVDNA &gt; 102 IU/mL patient decompensated liver cirrhosis : presence ascites , variceal hemorrhage , hepatic encephalopathy allergic ingredient drug patient complicate alcoholic liver disease , autoimmune liver disease , heretic liver disease , drug induce liver disease , nonalcoholic liver disease chronic liver disease . AFP &gt; 100ng/ml Cr &gt; 1.5×ULN pregnant woman patient severe disease organ failure patient tumor patient sever mental disease . patient disease condition investigator treat physician feel would interfere trial safety subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Compensated Liver Cirrhosis</keyword>
	<keyword>Early Antiviral Therapy</keyword>
	<keyword>Cost Effectiveness</keyword>
</DOC>